Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

European Medicines Agency accepts Mylan-Biocon's insulin glargine application

Glargine is one of the three insulin analogs being co-developed for the global marketplace by Mylan and Biocon - who are partners for a broad portfolio of biosimilars and insulin analogs

BS B2B Bureau  |  Bengaluru 

Biocon Ltd and Mylan NV on November 3, 2016 announced that the European Medicines Agency (EMA) has accepted for review Mylan's marketing authorization application (MAA) for insulin glargine, a long-acting insulin analog used to treat adults with type 2 diabetes and adults and pediatric patients (children 6 years and older) with type 1 diabetes for the control of high blood sugar. Mylan and Biocon, which have co-developed insulin glargine, look forward to offering another insulin treatment option for diabetic patients, who are often facing significant expense to manage their ...

TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH

Key stories on business-standard.com are available to premium subscribers only.

LOGIN

EMAIL / USER NAME
PASSWORD
REMEMBER ME Forgot password?

Not a member yet ? Resister Now

Connect using any below

  • Don't lose the opportunity of saving $26.77 per month
  • Don't lose the opportunity of saving $26.77 per month
Total Amount
Rs. 0.00
To proceed, kindly select a subscription package

WHAT YOU GET

On Business Standard Digital

  • Access your subscription from anywhere. Be it your computer, tablet or smartphone using a browser or the App, Your Choice.
  • Access to exclusive content, features, opinions and comment, hand-picked by our editors, just for you.
  • Pick your 5 favourite companies. Get all the news upates at the end of each day through E-Mail.
  • Pick the industry that you want to track. And get a daily news letter specific to that industry. Cut out the clutter.
  • And stay on top of your investments. Track stock prices in your portfolio
  • Access 18 years of archival data

On Digital

  • Seamless access to WSJ.com with your Business Standard digital account.
  • Experience the best of the Journal's reporting, video and interactive features.
  • Read about the people and events shaping business, finance, technology, politics, technology and culture.
  • Stay informed with newsletters - an easy way to get WSJ content straight to your inbox - making life easier on your busiest days.
  • More business executives read the Journal globally than any other publication.
*Note :
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital
First Published: Sat, November 05 2016. 14:15 IST
RECOMMENDED FOR YOU

European Medicines Agency accepts Mylan-Biocon's insulin glargine application

Glargine is one of the three insulin analogs being co-developed for the global marketplace by Mylan and Biocon - who are partners for a broad portfolio of biosimilars and insulin analogs

Glargine is one of the three insulin analogs being co-developed for the global marketplace by Mylan and Biocon - who are partners for a broad portfolio of biosimilars and insulin analogs Biocon Ltd and Mylan NV on November 3, 2016 announced that the European Medicines Agency (EMA) has accepted for review Mylan's marketing authorization application (MAA) for insulin glargine, a long-acting insulin analog used to treat adults with type 2 diabetes and adults and pediatric patients (children 6 years and older) with type 1 diabetes for the control of high blood sugar. Mylan and Biocon, which have co-developed insulin glargine, look forward to offering another insulin treatment option for diabetic patients, who are often facing significant expense to manage their ... image
Business Standard
177 22

European Medicines Agency accepts Mylan-Biocon's insulin glargine application

Glargine is one of the three insulin analogs being co-developed for the global marketplace by Mylan and Biocon - who are partners for a broad portfolio of biosimilars and insulin analogs

Biocon Ltd and Mylan NV on November 3, 2016 announced that the European Medicines Agency (EMA) has accepted for review Mylan's marketing authorization application (MAA) for insulin glargine, a long-acting insulin analog used to treat adults with type 2 diabetes and adults and pediatric patients (children 6 years and older) with type 1 diabetes for the control of high blood sugar. Mylan and Biocon, which have co-developed insulin glargine, look forward to offering another insulin treatment option for diabetic patients, who are often facing significant expense to manage their ...

image
Business Standard
177 22